Inflammation in Pulmonary Hypertension and Edema Induced by Hypobaric Hypoxia Exposure

Samia El Alam 1,2, Eduardo Pena 1,2,* Diego Aguilera 1, Patricia Siques 1,2 and Julio Brito 1,2

1 Institute of Health Studies, Arturo Prat University, Iquique 1100000, Chile
2 Institute DECIPHER, German-Chilean Institute for Research on Pulmonary Hypoxia and Its Health Sequelae, Hamburg (Germany) and Iquique (Chile), Avenida Arturo Prat 2120, Iquique 1110939, Chile
* Correspondence: eduardo.enrique.bio@gmail.com; Tel.: +56-57-252-6392

Abstract: Exposure to high altitudes generates a decrease in the partial pressure of oxygen, triggering a hypobaric hypoxic condition. This condition produces pathophysiologic alterations in an organism. In the lung, one of the principal responses to hypoxia is the development of hypoxic pulmonary vasoconstriction (HPV), which improves gas exchange. However, when HPV is exacerbated, it induces high-altitude pulmonary hypertension (HAPH). Another important illness in hypobaric hypoxia is high-altitude pulmonary edema (HAPE), which occurs under acute exposure. Several studies have shown that inflammatory processes are activated in high-altitude illnesses, highlighting the importance of the crosstalk between hypoxia and inflammation. The aim of this review is to determine the inflammatory pathways involved in hypobaric hypoxia, to investigate the key role of inflammation in lung pathologies, such as HAPH and HAPE, and to summarize different anti-inflammatory treatment approaches for these high-altitude illnesses. In conclusion, both HAPE and HAPH show an increase in inflammatory cell infiltration (macrophages and neutrophils), cytokine levels (IL-6, TNF-α and IL-1β), chemokine levels (MCP-1), and cell adhesion molecule levels (ICAM-1 and VCAM-1), and anti-inflammatory treatments (decreasing all inflammatory components mentioned above) seem to be promising mitigation strategies for treating lung pathologies associated with high-altitude exposure.

Keywords: inflammation; high altitude; pulmonary edema; pulmonary hypertension; hypoxia

1. Introduction

Studies have shown a strong relationship between the inflammatory process and the progression or aggravation of different pathologies [1–4], and there is evidence for crosstalk between hypoxia and inflammation that shows positive feedback between the stabilization and expression of hypoxia-inducible factor-1α (HIF-1α) and several inflammatory molecules [5,6]. Specifically, in response to hypobaric hypoxia, which is generated by high altitude exposure (>2500 m) and the decrease in the partial pressure of oxygen, the inflammatory process is rapidly activated in human subjects and animal models [7,8].

One of the principal responses in the lung to hypobaric hypoxia conditions is hypoxic pulmonary vasoconstriction (HPV). The physiological effects of HPV include pulmonary artery vasoconstriction, which redistributes the blood stream toward more ventilated areas of the lung, improving ventilation/perfusion matching and oxygen uptake [9,10]. However, when HPV is permanent, it activates molecular pathways that trigger pulmonary artery remodeling and, consequently, high-altitude pulmonary hypertension (HAPH). HAPH is classically defined as an increase in the mean pulmonary artery pressure (mPAP) of 30 mmHg or more [11,12].

Another pathology related to exacerbated HPV and subsequent HAPH under hypobaric hypoxic conditions is high-altitude pulmonary edema (HAPE), which is a noncardiogenic, acute, and potentially lethal pulmonary alteration [13]. HAPE is characterized by an increase in pulmonary arterial pressure and vasoconstriction. These conditions
increase vascular permeability in alveolar capillaries and ultimately aggravate hypoxic conditions [14–16].

The central effector mechanism of HPV is found within pulmonary artery smooth muscle cells (PASMCs) [10]. Recent work summarizes the alterations in molecular pathways in PASMCs that are related to HAPH, and inflammatory pathways seem to be important contributors to PASMC proliferation and pulmonary hypertension [17]. In addition to HAPH, HAPE may also be related to the inflammatory process; however, the latter exhibits some controversies, because some studies showed that inflammation could play a role in lung permeability in patients with HAPE [18], while others studies indicated that in humans, inflammation may be a secondary response to alveolar-capillary barrier disruption or edema [19].

Based on these findings, different studies have been performed to investigate preventative approaches for these pathologies related to high-altitude exposure, and the role of inflammation in response to these conditions was also examined [20–22]. Therefore, the aims of this review are to highlight the inflammatory pathways associated with hypobaric hypoxia, emphasize the key role of inflammation in lung pathologies, such as HAPH and HAPE, contribute to the understanding and identification of new biomarkers related to these high-altitude illnesses, and summarize different current anti-inflammatory approaches.

2. Hypoxia and Inflammation

In general, hypoxia can cause inflammation in an organism primarily by stimulating nuclear factor kappa B (NF-κB) gene transcription and the production of proinflammatory cytokines. Moreover, the reverse is also true since inflamed tissue can also become hypoxic [23]. The primary molecular responses to hypoxia are mediated by the transcription factor hypoxia-inducible factor (HIF). HIF regulates more than 200 genes and is present in several isoforms. Under hypobaric hypoxic conditions, the most studied isoform is HIF-1α [24,25].

Under normoxic conditions, HIF is hydroxylated at two proline residues through the prolyl hydroxylase (PHD) enzyme, where the Von Hippel–Lindau (VHL) ubiquitin ligase complex induces prolyl-hydroxylated HIF subunit degradation. However, under any hypoxic conditions, PHD hydroxylation activity is inhibited. This stabilizes HIF in the specific tissue or organism and contributes to the hypoxic mechanism [26]. Moreover, HIF-1α can also be stabilized by inflammatory molecules, such as IL-1β, NF-κB and TNF-α. NF-κB has been considered the master regulator of inflammation under hypoxic conditions since NF-κB can stabilize HIF-1α when it is released from inhibitory kinase b (IKb) through nuclear factor kinase subunit b (Ikkβ) activation [27]. Furthermore, a study showed that the regulatory protein of HIF, prolyl hydroxylase domain enzymes 2 (PHD2), serves as a coactivator of NF-κB in a HIF-1-independent fashion [28].

There is also evidence of crosstalk between HIF and the glucocorticoid receptor (GR). Glucocorticoids (GCs) are steroid hormones that play an important role in inflammation since they limit the production of most cytokines, such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-12, IL-18, TNF-α, and interferon-γ (INF-γ), to maintain homeostasis [29,30]. A study showed the upregulation of GR in human proximal tubular epithelial cells might occur through the binding of HIF-1α to one or more hypoxia responsive element (HRE) sites in the nuclear receptor subfamily 3, group C, member 1 (NR3C1) promotor, and it thereby enhances GR transcription [31]. However, in human alveolar epithelial cells exposed to hypoxia, there was a downregulation of both the mRNA and protein levels of GR [32] and the inhibition of the nuclear translocation of GR [33]. Interestingly, a study conducted by Vettori et al. [34] showed that GC can stabilize HIF-1α through inactivation of the VHL complex.

Moreover, hypoxia also increases the production of ROS and thus oxidative stress, and this condition is closely related to the inflammatory process [3]. For example, studies under normobaric hypoxic conditions showed that pulmonary artery hypertension is induced by an increase in NF-κB through the activation of ERK-1/2, which produces oxidative stress via Nox4-generated H₂O₂. In this process, ERK1/2, NF-κB, and H₂O₂...
contribute to the inhibition of peroxisome proliferator-activated receptor γ (PPARγ), which triggers pulmonary hypertension [35]. Under hypobaric hypoxic conditions, the crosstalk between oxidative stress and inflammation is important. Studies have demonstrated positive feedback between oxidative stress and inflammation, which recently has been coined “oxinflammation” [36,37]. Therefore, based on the mentioned evidence, there is an important role of inflammation under hypoxic conditions that could affect different tissues and organs, including the lung (Figure 1), which will be discussed below.

3. Lung Inflammation under Hypobaric Hypoxia

High-altitude or hypobaric hypoxia exposure can affect the immune homeostatic mechanism and immunoregulatory activities that may lead to several pathologies associated with this hypoxic condition [38]. Additionally, there is evidence that exposure to hypobaric hypoxia induces an inflammatory response [7]. Moreover, a study demonstrated an increase in the levels of IL-6 and the inflammatory biomarker IL-1 receptor antagonist in the serum of subjects exposed to high altitude, with a peak increase at Day 2 of exposure. Additionally, C-reactive protein (CRP) was increased in serum after 3 days of exposure [7]. In addition, a recent study in rats exposed to hypobaric hypoxic conditions for 72 h showed an increase in IL-1β in serum levels [21]. Therefore, it is important to highlight that there is an early inflammatory response after exposure to hypobaric hypoxia.

A moderate increase in circulating cytokine levels may reflect substantial inflammation in specific tissues, such as the lungs. Studies have demonstrated that under acute hypobaric hypoxia (3 h; 7620 m), there is an increase in the serum levels of proinflammatory cytokines (IL-1β, IL-6 and TNF-α) and neutrophil infiltration in the lungs of rats [39]. This is corroborated by a recent study that demonstrated an increase in inflammatory cell infiltration in the lungs of mice exposed to acute hypobaric hypoxia (7000 m; 7 days) [40]. Moreover, a recent study showed that the expression of inflammation-related genes (MMP8, MMP9, IL-17β, and Timp1) was upregulated in the lungs of rats exposed to the same conditions of hypoxia (acute hypobaric hypoxia) [21].

Additionally, the levels of inflammatory cytokines (TNF-α, IL-1β, and IL-6) were higher in the bronchoalveolar lavage of rats exposed to acute hypobaric hypoxia (6 h; 5000 m) plus inflammation induced by administration of lipopolysaccharides (LPS) than in that for each stimulus alone. Moreover, RT-qPCR data suggested that the combined stimulation of LPS and hypobaric hypoxia had a synergistic effect on gene expression levels in acute lung injury. This finding indicates that the promoter activity of toll-like receptor 4 (TLR4) was higher in the LPS plus hypobaric hypoxia group. Additionally, the inhibition

Figure 1. Proposed summary of the crosstalk between hypoxia and inflammation. Created with BioRender.com.

3. Lung Inflammation under Hypobaric Hypoxia

High-altitude or hypobaric hypoxia exposure can affect the immune homeostatic mechanism and immunoregulatory activities that may lead to several pathologies associated with this hypoxic condition [38]. Additionally, there is evidence that exposure to hypobaric hypoxia induces an inflammatory response [7]. Moreover, a study demonstrated an increase in the levels of IL-6 and the inflammatory biomarker IL-1 receptor antagonist in the serum of subjects exposed to high altitude, with a peak increase at Day 2 of exposure. Additionally, C-reactive protein (CRP) was increased in serum after 3 days of exposure [7]. In addition, a recent study in rats exposed to hypobaric hypoxic conditions for 72 h showed an increase in IL-1β in serum levels [21]. Therefore, it is important to highlight that there is an early inflammatory response after exposure to hypobaric hypoxia.

A moderate increase in circulating cytokine levels may reflect substantial inflammation in specific tissues, such as the lungs. Studies have demonstrated that under acute hypobaric hypoxia (3 h; 7620 m), there is an increase in the serum levels of proinflammatory cytokines (IL-1β, IL-6 and TNF-α) and neutrophil infiltration in the lungs of rats [39]. This is corroborated by a recent study that demonstrated an increase in inflammatory cell infiltration in the lungs of mice exposed to acute hypobaric hypoxia (7000 m; 7 days) [40]. Moreover, a recent study showed that the expression of inflammation-related genes (MMP8, MMP9, IL-17β, and Timp1) was upregulated in the lungs of rats exposed to the same conditions of hypoxia (acute hypobaric hypoxia) [21].

Additionally, the levels of inflammatory cytokines (TNF-α, IL-1β, and IL-6) were higher in the bronchoalveolar lavage of rats exposed to acute hypobaric hypoxia (6 h; 5000 m) plus inflammation induced by administration of lipopolysaccharides (LPS) than in that for each stimulus alone. Moreover, RT-qPCR data suggested that the combined stimulation of LPS and hypobaric hypoxia had a synergistic effect on gene expression levels in acute lung injury. This finding indicates that the promoter activity of toll-like receptor 4 (TLR4) was higher in the LPS plus hypobaric hypoxia group. Additionally, the inhibition

Figure 1. Proposed summary of the crosstalk between hypoxia and inflammation. Created with BioRender.com.
of HIF-1α increased the promoter activities of the TLR4 gene, showing the importance of the crosstalk between the HIF-1α and TLR4 pathways. The synergistic effect of inflammation and hypoxia exposure may be critical in the development of HAPE. Therefore, people with upper respiratory tract infections should avoid high-altitude exposure [41].

Regarding chronic hypobaric hypoxia, a study in rats also determined an increase in TNF-α expression in the lung tissue [42]. Additionally, a study in mice showed an increase in macrophages in the lung over the course of hypobaric hypoxia exposure, with a peak at Day 21 [43]. In fact, based on epidemiological studies of hypobaric hypoxia, there is an increase in both the genetic and protein levels of inflammatory biomarkers, such as IL-6, TNF-α, IL-1β, and IL-1α, and these biomarkers are present in different populations exposed to high altitudes (Andean and Tibetans) [44,45].

Particularly, the expression of IL-8 under this condition is controversial. Studies involving humans exposed to hypobaric hypoxia showed no changes in IL-8 levels in serum [38], but a previous study in endothelial cell cultures demonstrated an increase in this cytokine after 16 hours of exposure to hypobaric hypoxia [46]. Additionally, a study using rats exposed to chronic hypobaric hypoxia showed that the level of IL-8 was increased in lung tissue from the first day of exposure. This expression decreased over time, but it was still higher than that in the control group [47]. Therefore, the expression of IL-8 might depend on the time of exposure and type of tissue analyzed.

An interesting study in rats exposed to chronic hypobaric hypoxia showed an increase in 12(s)-hydroxyeicosatetraenoic acid (12(s)-HETE) expression in the lung, which was produced by leukocyte-type 12 lipoxygenase (12-LO) activation. This activation contributes to inflammatory pathways and the activation of ERK1/2 and p38 MAPK in smooth muscle cells (SMCs). Then, the proliferation process is stimulated, and HAPH subsequently develops [48]. Therefore, both acute and chronic exposure to high altitudes activate inflammatory pathways that contribute to the development of pulmonary high-altitude illnesses such as HAPE and HAPH (Figure 2), which will be discussed in the following sections.

4. High Altitude Pulmonary Edema

HAPE is a noncardiogenic pulmonary edema caused by pulmonary blood–gas barrier leakage in the lung. It can occur in rapidly ascending non-acclimatized individuals after arrival at altitudes above 2500 m, and profound hypoxemia and death may occur if the condition is not treated [49].

Inflammation might contribute to the pathogenesis of HAPE in susceptible individuals [7]. Although, Swenson et al. [50] claimed that HAPE is not related to inflammation
since there were no significant differences in the bronchoalveolar lavage levels of leukocytes, cytokines (IL-1β, IL-8 and TNF-α), and eicosanoids between subjects resistant or susceptible to HAPE at high altitudes. However, subsequent studies have analyzed cytokines to assess the underlying mechanisms of the development of HAPE. Patients with HAPE have increased TNF-α and IL-6 levels in serum [51]. Then, Sharma et al. [18] determined that the levels of TNF-α were increased in the blood of individuals with HAPE, and this alteration could have a role in lung permeability in patients with HAPE.

Studies in animal models also showed that cytokine levels were increased by hypoxia. Rats exposed to acute hypobaric hypoxia with signs of HAPE showed a 13-fold increase in NF-κB levels (nuclear fraction), and NF-κB regulated the increase in inflammatory molecules (IL-1, IL-6, and TNF-α) in lung tissue under this hypoxic condition, highlighting an increase in the levels of the cell adhesion molecules ICAM-1 and VCAM-1 [13].

Additionally, another study in rats with HAPE due to acute hypobaric hypoxia (9142 m for 5 h) also showed that the levels of proinflammatory molecules, such as TNF-α, monocyte chemoattractant protein-1 (MCP-1), INF-γ, IL-6, and TNF-β, in the bronchoalveolar lavage were increased, and the levels of NF-κB in lung nuclear extracts were increased [52]. MCP-1 and macrophage inflammatory protein-1α (MIP-1α) are important immune response modulators that can be altered by high-altitude exposure [38].

A subsequent study demonstrated that the levels of soluble urokinase-type plasminogen activator receptor (suPAR), a biomarker of inflammation, were increased along with CRP and IL-6 levels in the plasma of subjects exposed to acute hypobaric hypoxia [53]. However, since not all cases of HAPE had evidence of inflammation in the alveolar lavage fluid, inflammation could be a secondary response to alveolar–capillary barrier disruption or edema [19]. This topic still needs further study.

At the genetic level, a study in Han Chinese subjects with and without HAPE reported 12 single nucleotide polymorphisms (SNPs) in the NR3C1 gene between these groups; NR3C1 encodes human GR. Moreover, it is important to note that these polymorphisms were significantly associated with the risk of HAPE [54].

The inflammatory basis of HAPE pathophysiology is still debatable; thus, studies with a larger number of subjects are recommended for better understanding [55]. Therefore, although the role of inflammation in HAPE is unclear, there is an important increase in proinflammatory cytokines and chemokines that might modulate the development of HAPE (Figure 3). Different treatment approaches have been studied to diminish these factors and will be discussed later.
This proliferation process could be conditioned by inflammation. A proteomic study in rats exposed to intermittent hypobaric hypoxia (5500 m) showed that heat shock protein 70 (HSP70) and protein disulfide isomerase associated 3 (PDIA3), regulators of inflammation, modulate the development of vascular remodeling that occurs due to HAPH [58]. Moreover, PDIA3 has been related to an increase in inflammatory molecules (IL-1β, IL-6, and TNF-α) in the brain [59] and lung [60].

Moreover, HSP70 presents anti-inflammatory properties and plays a protective role in lung injury and fibrosis by inhibiting proinflammatory cytokine expression [61]. Preconditioning with a low dose of hypobaric hypoxia increased HSP70 in rats, and this attenuated the increase in inflammatory biomarkers in serum (TNF-α, IL-1β, E-selectin, and ICAM-1) [62]. It is important to note that these results have also been described in HAPE under the same experimental conditions [63].

Another important proinflammatory cytokine is macrophage migration inhibitory factor (MIF), which was upregulated in the lungs of rats with chronic hypobaric hypoxia-induced pulmonary hypertension. Interestingly, MIF stimulates rat PASMC proliferation. This probably occurs through the ERK1/2 and JNK pathways, without the involvement of p38 MAPK [64]. Other studies in rats with pulmonary hypertension induced by similar hypobaric hypoxia conditions showed an important infiltration of neutrophils in the lung and robust expression of phosphorylated NF-κB, IL-6, IL-1β, TNF-α, and VEGF. All these factors were decreased after resveratrol treatment [65], and these treatments (Table 1) will be discussed in the next section.
Table 1. Anti-inflammatory treatments for lung alterations due to hypobaric hypoxia.

| Treatment                      | Lung Injury | Animal Model       | Anti-Inflammatory Effects                                                                 | References          |
|--------------------------------|-------------|--------------------|-------------------------------------------------------------------------------------------|---------------------|
| Cobalt                         | HAPE        | Sprague Dawley rats| Decrease TNF-α, TNF-β, NF-κB, MCP-1, and IL-6; Increase HO-1 and MT                        | Shukla et al. [52]  |
| Curcumin                       | HAPE        | Sprague Dawley rats| Decrease NF-κB                                                                            | Sarada et al. [13]  |
| Nanocurcumin                   | HAPE        | Sprague Dawley rats| Decrease TNF-α, TNF-β, IL-6, and ET-1                                                     | Nehra et al. [66]   |
| Quercetin                      | HAPE        | Sprague Dawley rats| Downregulate NF-κB and TNF-α; Decreased ICAM-1, VCAM-1, and P-selectin; Increase TGF-β and IL-4 | Tripathi et al. [67]|
| Potentilla anserina L polysaccharide | HAPE      | Wistar rats        | Decrease IL-1β, TNF-α, IL-6; Inhibition HIF-1α and NF-κB                                   | Shi et al. [68]     |
| Hypobaric hypoxia preconditioning | HAPE        | Sprague Dawley rats| Increase HSP70                                                                            | Lin et al. [63]     |
| Netrine-1                      | HAPI        | Mice               | Reduced neutrophil infiltration; Decrease MIP-2                                             | Ko et al. [69]      |
| Cerium oxide nanoparticles     | HAPI        | Sprague Dawley rats| Decrease IL-1β, IL-6, and TNF-α; Decrease inflammatory cells infiltration                  | Arya et al. [39]    |
| Tadalafil                      | HAPH        | Wistar rats        | Decrease NF-κB and TNF-α; Decrease inflammatory cells infiltration                          | Rashid et al. [42]  |
| Magnesium lithospermate B      | HAPH        | Sprague Dawley rats| Downregulated HIF-1α and MCP-1 and NF-κB                                                   | Wang et al. [70]    |
| Intermittent Hypobaric hypoxia treatment | HAPH    | Sprague Dawley rats| Decrease NF-κB, TNF-α, and IL-6 and macrophage infiltration                                | Gao et al. [71]     |
| Resveratrol                    | HAPH        | Sprague Dawley rats| Decrease IL-6, IL-18, TNF-α, VEGF, and HIF-1α                                              | Xu et al. [65]      |

TNF-α, Tumor Necrosis Factor Alpha; TNF-β, Tumor Necrosis Factor Beta; HIF-1α, Hypoxia Inducible Factor-1α; MCP-1, Monocyte Chemoattractant Protein-1; NF-κB, Nuclear Factor-kappa B; IL-6, Interleukin-6; MIP-2, Macrophage Inflammatory Protein-2; IL-1β, Interleukin-1 beta; HO-1, Heme Oxygenase-1; MT, Metallothionein; ET-1, Endothelin-1; ICAM-1, Intercellular Adhesion Molecule-1; VCAM-1, Vascular Cell Adhesion Molecule-1; TGF-β, Transforming Growth Factor-beta; IL-4, interleukin-4; HSP70, Heat Shock Protein 70; HAPH, High Altitude Pulmonary Hypertension; HAPI, High Altitude Pulmonary Edema; HAPI, High Altitude Pulmonary Inflammation.

Additionally, endothelin-1 (ET-1) is a relevant molecule that plays a crucial role in promoting hypoxia-induced pulmonary hypertension, and ET-1 is a vasoconstrictor peptide that is produced by endothelial cells [72,73]. A study in rats demonstrated that circulating and lung ET-1 levels increased after acute hypobaric hypoxia exposure and were related to hypoxic pulmonary vasoconstriction [66]. It is important to note that several studies have demonstrated that ET-1 is strongly related to lung inflammation and fibrosis [74–76]. In vitro experiments showed that stimulation with ET-1 significantly enhanced IL-6 expression in pulmonary arterial endothelial cells [73]. Additionally, peroxisome proliferator-activated receptor γ (PPARγ) inactivation showed increased ET-1-induced vascular injury, probably through pro-oxidant and proinflammatory pathways (Figure 3) [77].

6. Treatments

The etiology of pulmonary hypertension is an important factor to consider when developing a treatment study. Interesting research has demonstrated that the administration of cilostazol (a vasodilator inhibitor of phosphodiesterase-3) prevented the pulmonary
hypertension induced by monocrotaline administration, but it was not effective in hypobaric hypoxia-induced pulmonary hypertension [78]. Additionally, it is important to note that the age of the experimental animal should be considered, as one study shows that the morphometric alterations in the lung induced by hypobaric hypoxia exposure are more exacerbated in older rats (24 months old) than in young rats (4 weeks old) [79].

Regarding anti-inflammatory approaches, Arya et al. [39] showed that inflammation signs in the lung of rats (increases in cytokines and neutrophil infiltration) were prevented by the administration of cerium oxide nanoparticles prior to hypobaric hypoxia exposure (7620 m; 6 h). In addition, pretreatment with netrine-1 (neuronal guidance protein-1) reduces neutrophil infiltration in the lungs of mice exposed to acute hypobaric hypoxia and attenuates the increase in macrophage inflammatory protein 2 (MIP-2) [69].

Dexamethasone is a synthetic glucocorticosteroid that is a potent anti-inflammatory drug that has also been used as a traditional prophylaxis for HAPE and other high-altitude illnesses, such as acute mountain sickness (AMS) and high-altitude cerebral edema (HACE) [19,80]. However, because of its diverse side effects [67,81], researchers have been proposing different anti-inflammatory approaches to reduce HAPE. A study determined that preconditioning with cobalt attenuated the pulmonary vascular leakage induced by hypobaric hypoxia in rats (9142 m; 5 h) and reduced inflammatory molecules, such as TNF-α/β, NF-κB, MCP-1, and IL-6 [52]. Another rat study showed that the administration of curcumin before hypobaric hypoxic exposure reduced signs of pulmonary edema and inhibited hypoxia-induced elevations in NF-κB levels [13]. A subsequent study in rats demonstrated that treatment with nanocurcumin was more effective than curcumin in reducing HAPE and pulmonary vascular medial wall thickness, and these changes were related to decreases in the levels of TNF-α, TNF-β, IL-6, and ET-1 in the plasma [66].

Other phytocompounds have been evaluated for the ability to reduce HAPE. Quercetin is a potent antioxidant and anti-inflammatory phytoflavonol. Administration of quercetin to rats 1 h prior to hypobaric hypoxia (7620 m; 6 h) exposure attenuated transvascular leakage after hypoxia exposure, downregulated NF-κB and TNF-α expression, decreased the expression of cell adhesion molecules (ICAM-1, VCAM-1, and P-selectin), and increased the expression of anti-inflammatory cytokines (TGF-β and IL-4) [67]. Pretreatment with Potentilla anserina L. polysaccharide in rats exposed to hypobaric hypoxia (8000 m; 72 h) ameliorated HAPE and decreased oxidative stress and the levels of proinflammatory cytokines (IL-1β, TNF-α, IL-6). In addition, hypobaric hypoxia increased the levels of HIF-1α and NF-κB, whereas pretreatment with this polysaccharide inhibited both transcription factors [68].

Regarding pulmonary artery hypertension induced by hypobaric hypoxic conditions, a study in rats under chronic hypobaric hypoxia determined that the oral administration of tadalafil, a phosphodiesterase-5 inhibitor considered a potent antioxidant, reduced oxidative stress, inflammation, and vasoconstriction. These three effects suggest that tadalafil could be considered a promising treatment option for pulmonary hypertension induced by hypobaric hypoxia [42]. A recent study in rats demonstrated that the administration of magnesium lithospermate B derived from Salvia miltiorrhiza reduces high altitude-induced pulmonary hypertension through the downregulation of HIF-1α, MCP-1, and NF-κB [70].

Furthermore, hypobaric hypoxia exposure could also be used as a treatment to minimize pulmonary pathologies. In a recent study, rats with monocrotaline-induced pulmonary artery hypertension were treated with chronic intermittent hypobaric hypoxia (6 h/day) for 4 weeks. In these rats, chronic intermittent hypobaric hypoxia attenuated PAH and remodeling, which was probably achieved by inhibiting the NF-κB/p38 MAPK pathway in the lung. In addition, the treatment reduced macrophage infiltration in lung tissue and proinflammatory cytokine expression (TNF-α and IL-6) [71]. A different study in rats showed that preconditioning with low doses of hypobaric hypoxia (1000 m, 5 h/day for 5 consecutive days for 2 weeks) reduces the pulmonary pathologies induced by hypobaric hypoxia exposure (6000 m; 24 h), such as HAPE, through a decrease in inflammatory molecules [63]. Therefore, we can hypothesize that preconditioning with low doses of hypo-
baric hypoxia could be a good strategy to abolish high-altitude pulmonary pathologies, which seems interesting and warrants further evaluation. Finally, it is important to note that anti-inflammatory studies of human subjects exposed to hypobaric hypoxia are rather scarce, and it is necessary to expand knowledge on this matter to improve treatment recommendations.

7. Conclusions

HAPE and HAPH induced by hypobaric hypoxia exposure are strongly related to increases in lung inflammation due to increases in inflammatory cell infiltration (macrophages and neutrophils), cytokine levels (IL-6, TNF-α and IL-1β), chemokine levels (MCP-1), and cell adhesion molecule levels (ICAM-1 and VCAM-1). These effects are reflected in systemic inflammation. The role of inflammation in the development of these diseases, specifically in HAPE, is not very clear in human studies, which could be considered a limitation and a new avenue for future research. Anti-inflammatory approaches, such as decreasing the previously mentioned inflammatory components, may be promising mitigating strategies for lung pathologies associated with high-altitude exposure and have been well evidenced in animal models, but more human studies or clinical trials are necessary to improve the prevention and treatment recommendations for these high-altitude illnesses. Therefore, this review suggests inflammatory target molecules that are involved in HAPE and HAPH pathologies, which could be considered as possible biomarkers in future studies. However, additional studies are needed to improve the understanding of the role of inflammation in high-altitude illnesses.

Author Contributions: S.E.A., E.P., D.A., P.S., and J.B. contributed to the conception of the review, the literature review, writing and draft preparation, review, and editing. All authors have read and agreed to the published version of the manuscript.

Funding: This review was funded by FIC GORE-TARAPACA grant BIP-400187737-0.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

HIF-1α  hypoxia-inducible factor-1α
GR     glucocorticoid receptor
MMP8   matrix metalloproteinase 8
MMP9   matrix metalloproteinase 9
IL-17β interleukin-17β
TIMP1  tissue inhibitor of metalloproteinase 1
NRF3C1 nuclear receptor subfamily 3, group C, member 1
ICAM-1 intercellular adhesion molecule-1
VCAM-1 vascular cell adhesion molecule 1
NF-kB  nuclear factor kappa B
TNF-α  tumor necrosis factor alpha
TLR4   toll-like receptor 4
12(s)-HETE 12(s)-hydroxyeicosatetraenoic acid
12-LO  leukocyte-type 12 lipoxygenase
suPAR soluble urokinase-type plasminogen activator receptor
MCP-1  monocyte chemoattractant protein-1
MIP-1α macrophage inflammatory protein-1α
HSP70  heat shock protein 70
PDIA3  protein disulfide isomerase associated 3
MIF    macrophage migration inhibitory factor
ET-1   endothelin 1
PPARγ  proliferator-activated receptor γ
MIP-2  macrophage inflammatory protein 2
References

1. Singh, N.; Baby, D.; Rajguru, J.P.; Patil, P.B.; Thakkannavar, S.S.; Pujari, V.B. Inflammation and cancer. *Ann. Afr. Med.* 2019, 18, 121–126. [CrossRef] [PubMed]

2. Agita, A.; Alsaqaff, M.T. Inflammation, immunity, and hypertension. *Acta Med. Indones.* 2017, 49, 158–165. [PubMed]

3. Pena, E.; Brito, J.; El Alam, S.; Siques, P. Oxidative stress, kinase activity and inflammatory implications in right ventricular hypertrophy and heart failure under hypoxic hypoxia. *Int. J. Mol. Sci.* 2020, 21, 6421. [CrossRef]

4. Bhattacharya, S.; Agarwal, S.; Shrimali, N.M.; Guchhait, P. Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases. *Mol. Aspects Med.* 2021, 81, 101000. [CrossRef] [PubMed]

5. Shay, J.E.; Simon, M.C. Hypoxia-inducible factors: Crosstalk between inflammation and metabolism. *Semin. Cell Dev. Biol.* 2012, 23, 389–394. [CrossRef]

6. Patel, H.; Zaghoul, N.; Lin, K.; Liu, S.F.; Miller, E.J.; Ahmed, M. Hypoxia-induced activation of specific members of the NF-kB family and its relevance to pulmonary vascular remodeling. *Int. J. Biochem. Cell Biol.* 2017, 92, 141–147. [CrossRef]

7. Hartmann, G.; Tschöp, M.; Fischer, R.; Bidlingmaier, C.; Riepl, R.; Tschöp, K.; Hautmann, H.; Endres, S.; Toepfer, M. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. *Cytokine* 2000, 12, 246–252. [CrossRef]

8. Maston, L.D.; Jones, D.T.; Giermakowska, W.; Resta, T.C.; Ramiro-Diaz, J.; Howard, T.A.; Jernigan, N.L.; Herbert, L.; Maurice, A.A.; Gonzalez Bosc, L.V. Interleukin-6 trans-signaling contributes to chronic hypoxia-induced pulmonary hypertension. *Pulm. Circ.* 2018, 8, 2045894018780734. [CrossRef]

9. Von Euler, U.S.; Liljestrand, G. Observations on the pulmonary arterial blood pressure in the cat. *Acta Physiol. Scand.* 1946, 12, 301–320. [CrossRef]

10. Dunham-Snary, K.J.; Wu, D.; Sykes, E.A.; Thakrar, A.; Parlow, L.; Mewburn, J.D.; Parlow, J.L.; Archer, S.L. Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to Medicine. *Chest* 2015, 151, 181–192. [CrossRef]

11. León-Velarde, F.; Maggiorini, M.; Reeves, J.T.; Aldashev, A.; Asmuss, I.; Bernardi, I.; Ge, R.L.; Hackett, P.; Kobayashi, T.; Moore, L.G.; et al. Consensus statement on chronic and subacute high altitude diseases. *High Alt. Med. Biol.* 2005, 6, 147–157. [CrossRef] [PubMed]

12. Mirrakhimov, A.; Strohl, K.P. High-altitude pulmonary hypertension: An update on disease pathogenesis and management. *Open Cardiovasc. Med. J.* 2016, 10, 19–27. [CrossRef] [PubMed]

13. Sarada, S.; Himadri, P.; Mishra, C.; Geetali, P.; Ram, M.S.; Iivazhagan, G. Role of oxidative stress and NFkB in hypoxia-induced pulmonary edema. *Exp. Biol. Med.* 2008, 233, 1088–1098. [CrossRef] [PubMed]

14. Hackett, P.H.; Roach, R.C. High-altitude illness. *N. Engl. J. Med.* 2001, 345, 107–114. [CrossRef]

15. Maggiorini, M.; Roca, H.P.B.L.; Peth, S.; Fischer, M.; Böhm, T.; Bernheim, A.; Kiencke, S.; Bloch, K.E.; Dehnerst, C.; Naeije, R.; et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. *Ann. Intern. Med.* 2006, 145, 497–506. [CrossRef]

16. Woods, P.; Alcock, J. High-altitude pulmonary edema. *Evol. Med. Public Health.* 2021, 9, 118–119. [CrossRef]

17. Siques, P.; Pena, E.; Brito, J.; El Alam, S. Oxidative Stress, Kinase Activation, and Inflammatory Pathways Involved in Effects on Smooth Muscle Cells During Pulmonary Artery Hypertension Under Hypobaric Hypoxia Exposure. *Front. Physiol.* 2021, 12, 690341. [CrossRef]

18. Sharma, M.; Singh, S.B.; Sarkar, S. Genome wide expression analysis suggests perturbation of vascular homeostasis during high altitude pulmonary edema. *PLoS ONE* 2014, 9, e85902. [CrossRef]

19. Swenson, E.R.; Bártfs, P. High-altitude pulmonary edema. *Compr. Physiol.* 2012, 2, 2753–2773. [CrossRef]

20. Nijiati, Y.; Maimaitiyiming, D.; Yang, T.; Li, H.; Aikemu, A. Research on the improvement of oxidative stress in rats with hypobaric hypoxia. *Respir. Res.* 2021, 22, 52. [CrossRef] [PubMed]

21. Cummins, E.P.; Keogh, C.E.; Crean, D.; Taylor, C.T. The role of HIF in immunity and inflammation. *Mol. Asp. Med.* 2016, 47–48, 24–34. [CrossRef] [PubMed]

22. Semenza, G.L. HIF-1 and mechanisms of hypoxia sensing. *Curr. Opin. Cell Biol.* 2001, 13, 167–171. [CrossRef]

23. Pena, E.; Siques, P.; Brito, J.; Arribas, S.M.; Böger, R.; Hannemann, J.; León-Velarde, F.; Gonzalez M.C.; López, M.R.; de Pablo, Á. Nox2 upregulation and p38 MAPK activation in right ventricular hypertrophy of rats exposed to long-term chronic intermittent hypobaric hypoxia. *Int. J. Mol. Sci.* 2020, 21, 8576. [CrossRef]

24. Samanta, D.; Semenza, G.L. Maintenance of redox homeostasis by hypoxia-inducible factors. *Redox Biol.* 2017, 13, 331–335. [CrossRef]

25. Pham, K.; Parikh, K.; Heinrich, E.C. Hypoxia and inflammation: Insights from high-altitude physiology. *Front. Physiol.* 2021, 12, 676782. [CrossRef]

26. Li, J.; Yuan, W.; Jiang, S.; Ye, W.; Yang, H.; Shapiro, L.M.; Risbud, M.V. Prolyl-4-hydroxylase domain protein 2 controls NF-κB/p65 transactivation and enhances the catabolic effects of inflammatory cytokines on cells of the nucleus pulposus. *J. Biol. Chem.* 2015, 290, 7195–7207. [CrossRef]

27. Shimba, A.; Ikuta, K. Control of immunity by glucocorticoids in health and disease. *Semin. Immunopathol.* 2020, 42, 669–680. [CrossRef]
30. Vanderhaeghen, T.; Beyaert, R.; Libert, C. Bidirectional crosstalk between hypoxia inducible factors and glucocorticoid signalling in health and disease. *Front. Immunol.* 2021, 12, 684085. [CrossRef]

31. Leonard, M.O.; Godson, C.; Brady, H.R.; Taylor, C.T. Potentiation of glucocorticoid activity in hypoxia through induction of the glucocorticoid receptor. *J. Immunol.* 2005, 174, 2230–2237. [CrossRef] [PubMed]

32. Huang, Y.; Zhao, J.J.; Lv, Y.Y.; Ding, P.S.; Liu, R.Y. Hypoxia down-regulates glucocorticoid receptor alpha and attenuates the anti-inflammatory actions of dexamethasone in human alveolar epithelial A549 cells. *Life Sci.* 2009, 85, 107–112. [CrossRef] [PubMed]

33. Zhang, P.; Fang, L.; Wu, H.; Ding, P.; Shen, Q.; Liu, R. Down-regulation of GRα expression and inhibition of its nuclear translocation by hypoxia. *Life Sci.* 2016, 146, 92–99. [CrossRef] [PubMed]

34. Vettori, A.; Greendall, D.; Wilson, G.K.; Peron, M.; Facchinello, N.; Markham, E.; Sinnakaran, M.; Matthews, L.C.; McKeating, J.A.; Argenton, F.; et al. Glucocorticoids promote Von Hippel Lindau degradation and Hif-1α stabilization. *Proc. Natl. Acad. Sci. USA* 2017, 114, 9948–9953. [CrossRef]

35. Lu, X.; Bijli, K.M.; Ramirez, A.; Murphy, T.C.; Kleinhенz, J.; Hart, C.M. Hypoxia downregulates PPARα via an ERK1/2/NF-κB-Nox4-dependent mechanism in human pulmonary artery smooth muscle cells. *Free Radic. Biol. Med.* 2013, 63, 151–160. [CrossRef]

36. Valacchi, G.; Virgili, F.; Cervellati, C.; Pecorelli, A. OxInflammation: From subclinical condition to pathological biomarker. *Front. Physiol.* 2018, 9, 858. [CrossRef]

37. Mrakic-Sposta, S.; Biagini, D.; Bondi, D.; Pietrangelo, T.; Vezzoli, A.; Lomonaco, T.; Di Francesco, F.; Verratti, V. OxInflammation: From subclinical condition to pathological biomarker. *Front. Physiol.* 2018, 9, 858. [CrossRef]

38. Rashid, M.; Fahim, M.; Kotwani, A. Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: Possible mechanisms. *Fundam. Clin. Pharmacol.* 2013, 27, 271–278. [CrossRef]

39. Yu, Y.R.; Mao, L.; Plantadosi, C.A.; Gunn, M.D. CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension. *Am. J. Respir. Cell Mol. Biol.* 2013, 48, 647–654. [CrossRef] [PubMed]

40. Foll, M.; Gaggiotti, O.E.; Daub, J.T.; Vatsiou, A.; Excoffier, L. Widespread signals of convergent adaptation to high altitude in Asia and america. *Am. J. Hum. Genet.* 2014, 95, 394–407. [CrossRef]

41. Bigham, A.W.; Lee, F.S. Human high-altitude adaptation: Forward genetics meets the HIF pathway. *Genes Dev.* 2014, 28, 2189–2204. [CrossRef] [PubMed]

42. Karakurum, M.; Shreeniwas, R.; Chen, J.; Pinsky, D.; Yan, S.D.; Anderson, M.; Sunouchi, K.; Major, J.; Hamilton, T.; Kuwabara, K.; et al. Hypoxic induction of interleukin-8 gene expression in human endothelial cells. *J. Clin. Investig.* 1994, 93, 1564–1570. [CrossRef]

43. Yu, Y.H.; Zhang, D.X.; Xiao, Z.H.; Huang, X.; Yang, Y.; Yang, C.; Gao, Y. Histone deacetylase inhibitors promote eNOS expression in vascular smooth muscle cells and suppress hypoxia-induced cell growth. *J. Cell. Mol. Med.* 2017, 21, 2022–2035. [CrossRef]
58. Ohata, Y; Ogata, S; Nakanishi, K; Kanazawa, F; Uenoyma, M; Hiroi, S; Tominaga, S; Toda, T; Kawai, T. Proteomic analysis of the lung in rats with hypobaric hypoxia-induced pulmonary hypertension. Histol. Histopathol. 2015, 28, 893–902. [CrossRef]
59. Wang, W.T.; Sun, L.; Sun, C.H. PDI3-regulated inflammation and oxidative stress contribute to the traumatic brain injury (TBI) in mice. Biochem. Biophys. Res. Commun. 2019, 518, 657–663. [CrossRef]
60. Chamberlain, N.; Korvin-Mihavics, B.R.; Nakada, E.M.; Bruno, S.R.; Heppner, D.E.; Chapman, D.G.; Hoffman, S.M.; van der Vliet, A.; Suratt, B.T.; Dienz, O.; et al. Lung epithelial protein disulfide isomerase A3 (PDI3A) plays an important role in influenza infection, inflammation, and airway mechanics. Redox Biol. 2019, 22, 101129. [CrossRef]
61. Tanaka, K.; Tanaka, Y.; Namba, T.; Azuma, A.; Mizushima, T. Heat shock protein 70 protects against bleomycin-induced pulmonary fibrosis in mice. Biochem. Pharmacol. 2010, 80, 920–931. [CrossRef] [PubMed]
62. Wang, C.T.; Lin, H.J.; Cheng, B.C.; Lin, M.T.; Chang, C.P. attenuating systemic inflammatory markers in simulated high-altitude exposure by heat shock protein 70-mediated hypobaric hypoxia preconditioning in rats. J. Formos. Med. Assoc. 2015, 114, 328–338. [CrossRef] [PubMed]
63. Lin, H.J.; Wang, C.T.; Niu, K.C.; Gao, C.; Li, Z.; Lin, M.T.; Chang, C.P. Hypobaric hypoxia preconditioning attenuates acute lung injury during high-altitude exposure in rats via up-regulating heat-shock protein 70. Clin. Sci. 2011, 121, 223–231. [CrossRef]
64. Zhang, B.; Shen, M.; Xu, M.; Liu, L.L.; Luo, Y.; Xu, D.Q.; Wang, Y.X.; Liu, M.L.; Liu, Y.; Dong, H.Y.; et al. Role of macrophage migration inhibitory factor in the proliferation of smooth muscle cell in pulmonary hypertension. Mediat. Inflamm. 2012, 2012, 840737. [CrossRef]
65. Xu, D.; Li, Y.; Zhang, B.; Wang, Y.; Liu, Y.; Luo, Y.; Niu, W.; Dong, M.; Liu, M.; Dong, H.; et al. Resveratrol alleviates hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats. Int. J. Med. Sci. 2016, 13, 942–954. [CrossRef] [PubMed]
66. Nehra, S.; Bharadwaj, V.; Bansal, A.; Saraswat, D. Nanocurcumin accords protection against acute hypobaric hypoxia induced lung injury in rats. J. Physiol. Biochem. 2016, 72, 763–779. [CrossRef]
67. Tripathi, A.; Kumar, B.; Sagi, S.S.K. Prophylactic efficacy of Quercetin in ameliorating the hypoxia induced vascular leakage in lungs of rats. PLoS ONE 2019, 14, e0219075. [CrossRef]
68. Shi, J.; Liu, Z.; Li, M.; Guo, J.; Chen, L.; Ding, L.; Ding, X.; Zhou, T.; Zhang, J. Polysaccharide from Potentilla anserina L ameliorate pulmonary edema induced by hypobaric hypoxia in rats. Biomed. Pharmacother. 2021, 139, 111669. [CrossRef]
69. Ko, C.L.; Lin, J.A.; Chen, K.Y.; Hsu, A.C.; Wu, S.Y.; Tai, Y.T.; Lin, K.H.; Chung, W.C.; Li, M.H. Netrin-1 dampens hypobaric hypoxia-induced lung injury in mice. High Alt. Med. Biol. 2019, 20, 293–302. [CrossRef]
70. Wang, Y.; Duo, D.; Yan, Y.; He, R.; Wu, X. Magnesium lithospermate B ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and its potential targets. Biomed. Pharmacother. 2020, 130, 110560. [CrossRef]
71. Gao, L.; Liu, J.; Hao, Y.; Zhao, Z.; Tan, H.; Zhang, J.; Meng, N.; Zheng, Q.; Wang, Z.; Zhang, Y. Chronic intermittent hypobaric hypoxia attenuates monocrotaline-induced pulmonary arterial hypertension via modulating inflammation and suppressing NF-κB/p38 pathway. Iran J. Basic Med. Sci. 2018, 21, 244–252. [CrossRef]
72. Modesti, P.A.; Vanni, S.; Morabito, M.; Modesti, A.; Marchetta, M.; Gamberi, T.; Sofi, F.; Savia, G.; Mancia, G.; Gensini, G.F.; et al. Role of endothelin-1 in exposure to high altitude: Aecotone mountain sickness and endothelin-1 (ACME-1) study. Circulation 2006, 114, 1410–1416. [CrossRef]
73. Satwiko, M.G.; Ikeda, K.; Nakayama, K.; Yagi, K.; Hocher, B.; Hirata, K.; Emoto, N. Targeted activation of endothelin-1 exacerbates hypoxia-induced pulmonary hypertension. Biochem. Biophys. Res. Commun. 2015, 465, 356–362. [CrossRef]
74. Hocher, B.; Schwarz, A.; Fagan, K.A.; Thöne-Reineke, C.; El-Hag, K.; Kusserow, H.; Elitok, S.; Bauer, C.; Neumayer, H.H.; Rodman, D.M.; et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am. J. Respir. Cell Mol. Biol. 2000, 23, 19–26. [CrossRef]
75. Donaubauer, B.; Busch, T.; Lachmann, R.; Deja, M.; Petersen, B.; Francis, R.; Träger, A.; Ebsen, M.; Boemke, W.; Kaisers, U. Low-dose inhalation of an endothelin-A receptor antagonist in experimental acute lung injury: ET-1 plasma concentration and pulmonary inflammation. Exp. Biol. Med. 2006, 231, 960–966. [CrossRef]
76. Kassuya, C.A.; Rogerio, A.P.; Calixto, J.B. The role of ET(A) and ET(B) receptor antagonists in acute and allergic inflammation in mice. Peptides 2008, 29, 1239–1327. [CrossRef]
77. Idris-Khodja, N.; Ouerd, S.; Trindade, M.; Gornitsky, J.; Rehman, A.; Barhoumi, T.; Offermanns, S.; Gonzalez, F.J.; Neves, M.F.; Paradis, P.; et al. Vascular smooth muscle cell peroxisome proliferator-activated receptor γ protects against endothelin-1-induced oxidative stress and inflammation. J. Hypertens. 2017, 35, 1390–1401. [CrossRef]
78. Ito, T.; Zhang, E.; Omori, A.; Kabwe, J.; Kawai, M.; Maruyama, J.; Okada, A.; Yokochi, A.; Sawada, H.; Mitani, Y.; et al. Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats. BMC Pulm. Med. 2021, 21, 377. [CrossRef]
79. Nesterov, Y.V. Age features of the reaction of the lung tissue and surfactant to hypobaric hypoxia and hyperbaric hyperoxia in the experiment. Adv. Gerontol. 2019, 32, 985–989. [CrossRef]
80. Davis, C.; Hackett, P. Advances in the Prevention and Treatment of High Altitude Illness. Emerg. Med. Clin. North Am. 2017, 35, 241–260. [CrossRef]
81. Patir, H.; Sarada, S.K.; Singh, S.; Mathew, T.; Singh, B.; Bansal, A. Quercetin as a prophylactic measure against high altitude cerebral edema. Free Radic. Biol. Med. 2012, 53, 659–668. [CrossRef] [PubMed]